A useful update was provided at a meeting this week sponsored by the Royal National Institute for the Blind (RNIB) and Patients Involved in NICE (the National Institute for Health and Clinical Excellence). As the proceedings are to be written up and published, I focus here on the key points that emerged for me. […]
Tag: health economics
NICE and the influenza antivirals for healthy adults – No, again and again and again
NICE’s latest technology appraisal of the flu antiviral drugs (amantadine, oseltamivir and zanamivir), published in February 2009 marks the sixth time these drugs have been considered. The timelines are shown below. […]